Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma

Radiat Med. 2008 May;26(4):206-12. doi: 10.1007/s11604-007-0216-5. Epub 2008 May 29.

Abstract

Purpose: The aim of this study was to assess the incidence, degree, and predictors of hepatic arterial damage (HAD) after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Materials and methods: A total of 33 patients with unresectable HCC underwent TACE alone using a mixture of iodized oil, epirubicin, and gelatin sponge. A follow-up angiogram was available for 76 of 109 sessions, and HAD was evaluated at each subsegment of the hepatic artery using a three-grade scale (1, no or slight wall irregularity; 2, overt stenosis; 3, occlusion). Grades 2 and 3 were considered to indicate significant HAD. The predictors of HAD were analyzed by multivariate analysis.

Results: A total of 161 hepatic arteries were embolized from the lobar (n = 43), segmental (n = 40), subsegmental (n = 72), or more distal (n = 6) level. The follow-up period between the initial and last sessions ranged from 70 to 1505 days (median 497 days). Significant HAD occurred in 37 of 231 subsegmental hepatic arteries (16%) and in 16 of 33 patients (48%). The accumulated dose of epirubicin per artery (P = 0.001) and Child-Pugh score (P < 0.001) were significant predictors.

Conclusion: TACE is more likely to induce HAD in cirrhotic patients with impaired liver function and when a high dose of the chemotherapeutic agent was used.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiography
  • Antibiotics, Antineoplastic / administration & dosage
  • Carcinoma, Hepatocellular / therapy*
  • Chemoembolization, Therapeutic / adverse effects*
  • Contrast Media / administration & dosage
  • Epirubicin / administration & dosage
  • Female
  • Gelatin Sponge, Absorbable / administration & dosage
  • Hemostatics / administration & dosage
  • Hepatic Artery / diagnostic imaging*
  • Hepatic Artery / injuries*
  • Humans
  • Iodized Oil / administration & dosage
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Survival Rate
  • Treatment Outcome

Substances

  • Antibiotics, Antineoplastic
  • Contrast Media
  • Hemostatics
  • Epirubicin
  • Iodized Oil